Filtered By:
Specialty: Drugs & Pharmacology
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1747 results found since Jan 2013.
NHS Choices "Behind the Headlines Assessment": Swine flu jab narcolepsy risk is very small
Source: NHS Choices
Area: News
The Behind the Headlines service from NHS Choices has featured a quality assessment of a study published in the BMJ and reported widely in the media. The study (designed as a retrospective analysis) found an increased risk of narcolepsy after vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine (Pandemrix vaccine), thus suggesting a causal association.
The NHS Choices assessment acknowledges that the media reports are underpinned by "a well-conducted, government-funded study that confirms findings of previous research from Finland". However, it also stresses that the risk...
Source: NeLM - News - February 28, 2013 Category: Drugs & Pharmacology Source Type: news
Flu vaccine helps unravel complex causes of narcolepsy
The link between a strange sleep disorder and a swine flu vaccine has been found, raising hopes of safer vaccines and an insight into autoimmune disease
Source: New Scientist - Drugs and Alcohol - December 18, 2013 Category: Drugs & Pharmacology Source Type: research
Pitolisant (Wakix) for Narcolepsy
Date: February 8, 2021
Issue #:
1617Summary:
The FDA has approved pitolisant (Wakix– Harmony), a
histamine-3 (H3)-receptor antagonist/inverse agonist,
for treatment of excessive daytime sleepiness (EDS)
or cataplexy in adults with narcolepsy. It is the first
H3-receptor antagonist/inverse agonist to become
available in the US and the first non-controlled substance
to receive FDA approval for these indications.
Pitolisant has been available in Europe since 2016.
Source: The Medical Letter - January 12, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Adderall Alertec Amphetamine Anafranil armodafinil Clomipramine Effexor fluoxetine Methylphenidate Narcolepsy Nuvigil pitolisant Provigil Prozac Ritalin SNRIs Sodium oxybate solriamfetol SSRIS Sunosi Tricyclic antid Source Type: research
Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy.
Authors: Sullivan SS, Guilleminault C
Abstract
INTRODUCTION: Obstructive sleep apnea (OSA) and narcolepsy are sleep disorders associated with high prevalence and high symptomatic burden including prominent sleepiness, daytime dysfunction and poor nocturnal sleep. Both have elevated risk of poor health outcomes. Current therapies are often underutilized, cumbersome, costly or associated with residual symptoms.
AREAS COVERED: This review covers current available therapies for OSA and narcolepsy as well as discusses areas for potential drug development, and agents in the therapeutic pipeline, including the cannabi...
Source: Expert Opinion on Emerging Drugs - February 17, 2016 Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
Pharmacological management of narcolepsy with and without cataplexy.
Authors: Kallweit U, Bassetti CL
Abstract
Introduction Narcolepsy is an orphan neurological disease and presents with sleep- wake, motoric, neuropsychiatric and metabolic symptoms. Narcolepsy with cataplexy is most commonly caused by an immune-mediated process including genetic and environmental factors, resulting in the selective loss of hypocretin-producing neurons. Narcolepsy has a major impact on workableness and quality of life. Areas covered This review provides an overview of the temporal available treatment options for narcolepsy (type 1 and 2) in adults, including authorization status by regulatory agencie...
Source: Expert Opinion on Pharmacotherapy - April 28, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
An Overview of Hypocretin based Therapy in Narcolepsy.
Authors: Takenoshita S, Sakai N, Chiba Y, Matsumura M, Yamaguchi M, Nishino S
Abstract
INTRODUCTION: Narcolepsy with cataplexy is most commonly caused by a loss of hypocretin/orexin peptide-producing neurons in the hypothalamus (i.e., Narcolepsy Type 1). Since hypocretin deficiency is assumed to be the main cause of narcoleptic symptoms, hypocretin replacement will be the most essential treatment for narcolepsy. Unfortunately, this option is still not available clinically. There are many potential approaches to replace hypocretin in the brain for narcolepsy such as intranasal administration of hypocretin peptides, ...
Source: Expert Opinion on Investigational Drugs - April 7, 2018 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Learning from history: do not flatten the curve of antiviral research!
Abstract
Here, we explore the dynamics of the response of the scientific community to several epidemics, including Coronavirus 2019 (COVID-19), as assessed by the numbers of clinical trials, publications, and level of research funding over time. All six prior epidemics studied [bird flu, severe acute respiratory syndrome (SARS), swine flu, Middle East Respiratory Syndrome (MERS), Ebola, and Zika] were characterized by an initial spike of research response that flattened shortly thereafter. Unfortunately, no antiviral medications have been discovered to date as treatments for any of these diseases. By contrast, the...
Source: Drug Discovery Today - July 14, 2020 Category: Drugs & Pharmacology Authors: Bobrowski T, Melo-Filho CC, Korn D, Alves VM, Popov KI, Auerbach S, Schmitt C, Moorman NJ, Muratov EN, Tropsha A Tags: Drug Discov Today Source Type: research
Spontaneous reporting of suspected narcolepsy after vaccination against pandemic influenza A (H1N1) in Germany
ConclusionsCompared with the prepandemic background incidence rate, the number of incident narcolepsy cases was 3.8‐fold and 2.8‐fold as high.
Source: Pharmacoepidemiology and Drug Safety - August 14, 2017 Category: Drugs & Pharmacology Authors: Doris Oberle, Jutta Pavel, Brigitte Keller ‐Stanislawski Tags: ORIGINAL REPORT Source Type: research
An evaluation of sodium oxybate as a treatment option for narcolepsy.
Authors: Abad VC
Abstract
Introduction: Narcolepsy is a lifelong central nervous system (CNS) disorder characterized by excessive daytime sleepiness, cataplexy, disturbed nocturnal sleep, hypnagogic hallucinations, and sleep paralysis. Treatment is symptomatic and challenging. Current therapies with wake promoting agents, stimulants, and antidepressants improve symptoms but residual sleepiness or cataplexy may persist. Drug tolerance may develop. Adverse drug effects limit therapy. In the United States, sodium oxybate has been approved to treat daytime sleepiness and cataplexy in adults with narcolepsy since 2002. ...
Source: Expert Opinion on Pharmacotherapy - May 30, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Evaluating pitolisant as a narcolepsy treatment option.
Authors: de Biase S, Pellitteri G, Gigli GL, Valente M
Abstract
INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. Treatment of narcolepsy remains challenging and current therapy is strictly symptomatically based.
AREAS COVERED: The present manuscript is based on an extensive Internet and PubMed search from 1990 to 2020. It is focused on the clinical and pharmacological properties of pitolisant in the treatment of narcolepsy.
EXPERT OPINION: Cur...
Source: Expert Opinion on Pharmacotherapy - September 19, 2020 Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Solriamfetol Titration & amp; AdministRaTion (START) in Patients With Narcolepsy
This study characterized real-world titration strategies for patients with narcolepsy (with or without comorbid OSA) initiating solriamfetol therapy.METHODS: This virtual, descriptive study included a retrospective medical record review and qualitative survey. US-based physicians prescribing solriamfetol for EDS associated with narcolepsy or OSA participated. Data are reported for patients with narcolepsy with or without comorbid OSA (OSA alone reported separately). On the basis of medical record review, titration strategies were classified de novo (EDS medication naive), transition (switched or switching from existing EDS...
Source: Clinical Therapeutics - September 28, 2022 Category: Drugs & Pharmacology Authors: Michael J Thorpy Danielle Hyman Gregory S Parks Abby Chen Catherine Foley Beth Baldys Diane Ito Haramandeep Singh Source Type: research
Investigational therapies for the treatment of narcolepsy.
Authors: de Biase S, Nilo A, Gigli GL, Valente M
Abstract
INTRODUCTION: Narcolepsy is a chronic sleep disorder characterized by a pentad of excessive daytime sleepiness (EDS), cataplexy, sleep paralysis, hypnagogic/hypnopompic hallucinations, and disturbed nocturnal sleep. While non-pharmacological treatments are sometimes helpful, more than 90% of narcoleptic patients require a pharmacological treatment. Areas covered: The present review is based on an extensive Internet and PubMed search from 1994 to 2017. It is focused on drugs currently in development for the treatment of narcolepsy. Expert opinion: Currently t...
Source: Expert Opinion on Investigational Drugs - July 22, 2017 Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research
Pitolisant for treating patients with narcolepsy.
This article aims to review pitolisant.Areas covered: In this paper the chemical properties, mechanism of action, pharmacokinetics, clinical efficacy and safety of pitolisant was introduced, and the development course of drugs for treating narcolepsy is also briefly described. We performed a systematic review of the literature using PubMed and the following keywords were used: "pitolisant" and "narcolepsy", "cataplexy" and "excessive daytime sleepiness" and "histamine 3 receptor".Expert opinion: Pitolisant is a histamine 3 receptor antagonist/inverse agonist. It can activate histamine release in the brain and enhances wake...
Source: Pharmacological Reviews - January 14, 2020 Category: Drugs & Pharmacology Authors: Li S, Yang J Tags: Expert Rev Clin Pharmacol Source Type: research
